KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer
- Jung-Jin Park1, 4,
- Yeung Bae Jin1,
- Yoon-Jin Lee1,
- Jae-Seon Lee2,
- Yun-Sil Lee3,
- Young-Gyu Ko†4Email author and
- Minyoung Lee†1Email author
© Park et al; licensee BioMed Central Ltd. 2012
Received: 26 July 2011
Accepted: 6 March 2012
Published: 6 March 2012
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|26 Jul 2011||Submitted||Original manuscript|
|Resubmission - Version 2|
|Submitted||Manuscript version 2|
|29 Oct 2011||Reviewed||Reviewer Report - Khalil Ahmed|
|31 Oct 2011||Reviewed||Reviewer Report - Joanne Edwards|
|31 Oct 2011||Reviewed||Reviewer Report - Severine Van slambrouck|
|2 Dec 2011||Author responded||Author comments - Minyoung Lee|
|Resubmission - Version 3|
|2 Dec 2011||Submitted||Manuscript version 3|
|6 Dec 2011||Reviewed||Reviewer Report - Joanne Edwards|
|19 Dec 2011||Reviewed||Reviewer Report - Khalil Ahmed|
|Resubmission - Version 4|
|Submitted||Manuscript version 4|
|6 Mar 2012||Editorially accepted|
|6 Mar 2012||Article published||10.1186/1471-2407-12-81|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.